<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20221221056887N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-03-06</date_registration>
      <primary_sponsor>Kerman University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the effect of mouthwash containing an acidophilic strain of Lactobacillus brevis enriched with selenium on the microbial flora of the gastrointestinal tract and the healing of oral ulcers in ICU patients of Shahid Bahonar Medical Center, Kerman.</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the effect of mouthwash containing an acidophilic strain of Lactobacillus brevis enriched with selenium on the microbial flora of the gastrointestinal tract and the healing of oral ulcers in ICU patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-04-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/68726</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: After examining the patients in terms of the criteria for entering the study and obtaining informed consent, the total number of people with conditions for entering the study will be divided into two equal groups, and the placement of people in these two groups will be in the form of block randomization with the blinding process (in If the total sample size is not available for block randomization at the beginning of the study, randomization using random number table method is used, Blinding description: This study has been double-blind, so that the patient, the clinical caregiver, the evaluator, and the outcome researcher do not know the type of mouthwash prescribed, and it is only prescribed based on mouthwash number 1, 2, and 3.</study_design>
      <phase>3</phase>
      <hc_freetext>Condition 1: oral ulcer. Condition 2: Changing the flora of the digestive tract.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: The studied mouthwash (produced in Kerman University of Medical Sciences, Iran, where Lactobacillus isolated from dairy and edible products is cultured in an environment containing selenium salt to be enriched with selenium, and after laboratory approval of the bacteria for human use daily 4 50 cc of normal saline 0.9% containing 109 cfu of this probiotic for 30 seconds is prescribed for patients as a mouthwash for one week. Intervention 2: Intervention group: Chlorhexidine mouthwash (manufactured by Vi One-Iran, which is diluted to a concentration of 0.12% and then 50 cc of this mouthwash is prescribed to the patients 4 times a day for 30 seconds for a week). Intervention 3: Control group: normal saline 0.9% (manufactured by Iran-Iran company, which is used at a concentration of 0.9% and 50cc of this mouthwash is prescribed to patients 4 times a day for 30 seconds for a week).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Project data will be published without mentioning personal information and identification of study subjects

When:
Access starts from the publication of the final report

To whom:
The data that can be published is published in the form of a final report and is available to everyone

Conditions:
The data that can be published will be announced in the final report of the plan

Where to obtain:
Kerman University of Medical Sciences, Medical University Campus, 
  Haft-Bagh Highway, Kerman, Iran

How to obtain:
After the completion of the project (1 year)

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Farshid Ataollahi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Qaraney St, Next to Shahid Bahonar Hospital, Upper Floor 0f Pharmacy No.2 , Kerman, Iran</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7616911319</zip>
        <telephone>+98 34 3223 8942</telephone>
        <email>farshid.ataollahi@gmail.com</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Farshid Ataollahi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Qaraney St, Next to Shahid Bahonar Hospital, Upper Floor 0f Pharmacy No.2 , Kerman, Iran</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7616911319</zip>
        <telephone>+98 34 3223 8942</telephone>
        <email>farshid.ataollahi@gmail.com</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Being hospitalized in the ICU department of Bahnar Hospital
No sepsis, pneumonia, or other active infection
No known immunodeficiency
For intubated patients, cases that the intubation tube is cuffed are selected</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>The patient was discharged from the ICU and anesthesia service of Bahnar Hospital</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K12.1</hc_code>
      <hc_code>A09</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other forms of stomatitis</hc_keyword>
      <hc_keyword>Infectious gastroenteritis and colitis, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The studied mouthwash (produced in Kerman University of Medical Sciences, Iran, where Lactobacillus isolated from dairy and edible products is cultured in an environment containing selenium salt to be enriched with selenium, and after laboratory approval of the bacteria for human use daily 4 50 cc of normal saline 0.9% containing 109 cfu of this probiotic for 30 seconds is prescribed for patients as a mouthwash for one week.</i_keyword>
      <i_keyword>Intervention group: Chlorhexidine mouthwash (manufactured by Vi One-Iran, which is diluted to a concentration of 0.12% and then 50 cc of this mouthwash is prescribed to the patients 4 times a day for 30 seconds for a week)</i_keyword>
      <i_keyword>Control group: normal saline 0.9% (manufactured by Iran-Iran company, which is used at a concentration of 0.9% and 50cc of this mouthwash is prescribed to patients 4 times a day for 30 seconds for a week)</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Oral ulcer. Timepoint: The entire duration of drug administration. Method of measurement: Observation and examination of the wound by the researcher(wound healing time AND Wound dimensions).</prim_outcome>
      <prim_outcome>Gastrointestinal flora. Timepoint: The beginning and the end of the study and according to the routine of the department. Method of measurement: The information available in the system and the response section of the patient's tests(Microbial flora of the pharynx).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name>Biotechnology Development Headquarters</sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Kerman University of Medical Sciences</source_name>
      <source_name>Biotechnology Development Headquarters</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-02-06</approval_date>
        <contact_name>Ethics committee of Kerman University of Medical Sciences</contact_name>
        <contact_address>Jahad Blvd. Ebn Sina Avenue, Kerman, Iran Kerman Kerman Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
